Myriad Genetics, Inc. has announced its financial results for the third quarter of 2026, revealing a revenue increase and a strategic shift in its business focus. The company reported third-quarter revenue of $202.7 million, a 6% sequential increase, although it represents a 1% decrease compared to the same period last year. The results come alongside the announcement of a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash, a move intended to support Myriad's growth initiatives in the Cancer Care Continuum.

On November 4, 2026, Myriad Genetics filed an 8-K with the SEC detailing these developments. The filing included financial highlights and the company's strategic objectives. Sam Raha, President and CEO of Myriad Genetics, emphasized the importance of the sale, stating, "The sale of our Prenatal Health business is a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum including screening, treatment selection and monitoring along with remission surveillance." This statement underscores the company's commitment to enhancing its core offerings in cancer diagnostics.

Background

Myriad Genetics, Inc. is a leader in molecular diagnostic testing and precision medicine, incorporated in Delaware. The company operates under the SIC classification of 2835, which pertains to In Vitro & In Vivo Diagnostic Substances. Myriad's stock is traded on the Nasdaq under the ticker MYGN. The latest filing, dated November 4, 2026, is part of a series of recent filings that include various forms such as 4 and Schedule 13G/A, indicating ongoing corporate activity.

What the Filing Says

The SEC filing states, "On November 4, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2026." It also mentions that the earnings release is attached as Exhibit 99.1. The company has raised the mid-point of its full-year 2026 revenue guidance, reflecting positive trends and the impact of the strategic sale.

Impact

The decision to sell the Prenatal Health business is expected to strengthen Myriad's balance sheet and enhance its focus on cancer-related diagnostics. This strategic pivot may influence competitors within the diagnostic substances sector as Myriad reallocates resources and refines its market approach. The emphasis on the Cancer Care Continuum aligns with broader industry trends toward personalized medicine and targeted therapies.

What's Next

The filing does not specify what happens next, but the anticipated closure of the Prenatal Health business sale by early 2027 suggests that Myriad will continue to refine its operations and focus on its core competencies in cancer diagnostics.